• Fluomizin (Dequalinium chloride) 10mg 6 vaginal tablets

Expiration date: 01/2025

Composition and form of release:

Vaginal tablets, active substance:

dequalinium chloride 10 mg

excipients: lactose monohydrate MCC magnesium stearate

in contour cell packages aluminum foil / PVC 6 pcs. in a pack of cardboard 1 contour cell package.

Description of the dosage form:

Tablets are biconvex round in shape, white in color.


With intravaginal administration, an extremely small amount of dequalinium chloride is absorbed through the vaginal mucosa into the systemic bloodstream, metabolized to a derivative of 2, 2-dicarboxylic acid, and excreted in an unconjugated form through the intestine.

Description of pharmacological action:

Fluomizin contains the active substance dequalinium chloride, which is a quaternary ammonium compound with a wide spectrum of antimicrobial activity. Dequalinium chloride is active against most gram-positive bacteria Streptococcus spp., including beta-hemolytic streptococci of groups A and B, Staphylococcus aureus, Listeria spp., anaerobes Peptostreptococcus (group D), fungi of the genus Candida (Candida tropicalis, Candida albicans, Candida glabrata), gram-negative bacteria Gardnerella vaginalis, Escherichia coli, Serratia spp., Klebsiella spp., Pseudomonas spp., Proteus spp. and protozoa (Trichomonas vaginalis).


  • bacterial vaginosis
  • candida vaginitis
  • trichomonas vaginitis
  • vaginal sanitation before gynecological operations and childbirth.


  • hypersensitivity to the components of the drug
  • ulcerative lesions of the epithelium of the vagina and cervix.
  • It is not recommended to use dequalinium chloride before sexual activity.

Use during pregnancy and lactation:

The drug is approved for use during the entire period of pregnancy and lactation.

Side effect:

Extremely rarely, local reactions of irritation (erosion), itching, burning or redness of the vaginal mucosa can be observed. However, these adverse reactions may also be associated with symptoms of a vaginal infection.

Extremely rare-fever, allergic reactions.

Drug interaction:

Fluomizine is incompatible with soap and other anionic surfactants.

Method of administration and dosage:


The recommended dosage regimen is 1 vaginal tablet per day. The vaginal tablet is injected deep into the vagina in the evening before going to bed, lying on your back, slightly bending your legs.

During menstruation, treatment should be discontinued and continue the previous course after it ends.

It is necessary to conduct a full course of treatment (6 days) to avoid relapse.


There are no data on overdose. With intravaginal use, an overdose is unlikely.

Safety precautions:

Fluomizin contains excipients that sometimes do not completely dissolve in the vagina. Therefore, the remnants of the vaginal pill can be found on the underwear. This does not affect the effectiveness of the drug Fluomizin.

In rare cases, with excessive vaginal dryness, there is a chance that the tablet will remain undissolved. To prevent this, before you enter the vaginal tablet, it must be moistened with water (for 1 s under running water).

During the treatment period, it is recommended to change the pads and underwear more often. If clinical signs of infection persist after treatment is completed, a second microbiological examination should be performed to identify the pathogen and confirm the diagnosis.

During treatment with the drug, it is recommended to refrain from sexual contact. To prevent urogenital reinfection, simultaneous treatment of sexual partners is necessary.

Influence on the ability to drive a car or perform work that requires increased speed of physical and mental reactions. The drug does not affect the performance of potentially dangerous activities that require special attention and speed of psychomotor reactions (driving, etc.)


  • $22.00